Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Science Translational Medicine|April 5, 2023
T<sub>STEM</sub>-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical modelsDeborah Meyran, Joe Jiang Zhu, Jeanne Butler, et al.
NPJ Precision Oncology|May 7, 2026
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseasesSarah Childs, David Ma, Elizabeth Houghton, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Ejhaem|August 19, 2024
Variation in immunoglobulin use and impact on survival in myelomaKhai Li Chai, Cameron Wellard, Ltp Thao, et al.
Nature|July 3, 2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload deliveryAmanda X Y Chen, Kah Min Yap, Joelle S Kim, et al.
The New England Journal of Medicine|February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.
Nature|April 10, 2024
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacyJack D Chan, Christina M Scheffler, Isabelle Munoz, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Science Translational Medicine|April 5, 2023
T<sub>STEM</sub>-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical modelsDeborah Meyran, Joe Jiang Zhu, Jeanne Butler, et al.
NPJ Precision Oncology|May 7, 2026
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseasesSarah Childs, David Ma, Elizabeth Houghton, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood|March 12, 2017
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationNadine Hein, Donald P Cameron, Katherine M Hannan, et al.
Ejhaem|August 19, 2024
Variation in immunoglobulin use and impact on survival in myelomaKhai Li Chai, Cameron Wellard, Ltp Thao, et al.
Nature|July 3, 2025
Rewiring endogenous genes in CAR T cells for tumour-restricted payload deliveryAmanda X Y Chen, Kah Min Yap, Joelle S Kim, et al.
The New England Journal of Medicine|February 12, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory MyelomaSimon J Harrison, Cyrille Touzeau, Nicolas Kint, et al.
Nature|April 10, 2024
FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacyJack D Chan, Christina M Scheffler, Isabelle Munoz, et al.
Pageof 16